Pinetree Therapeutics News

AZ Takes Full Control of Pinetree EGFR Degrader

April 30, 2026

AstraZeneca exercised its option for Pinetree's PTX-299 EGFR degrader, paying $25M and triggering full licence for $500M+ potential value.